FDA-Cleared AI Device

Cleerly

Cleerly

Automated analysis of coronary CT angiography that quantifies stenosis and characterizes plaque by volume and composition rather than reporting stenosis severity alone.

At A Glance

Manufacturer
Cleerly
Medical specialty
Cardiology
Clearance route
510(k)
Year authorized
2019 onward
Modality
Coronary CT angiography
Role in workflow
Quantification

The argument behind plaque quantification is that percent stenosis is a poor predictor of which lesion causes an event. Composition and total burden carry information stenosis grading discards, and human readers cannot practically quantify either at scale.

Where It Is Used

  • Coronary plaque burden quantification
  • Non-calcified plaque characterization
  • Serial assessment of plaque progression under therapy

Limitations Worth Knowing

Plaque quantification thresholds are not yet standardized across vendors, and outcome data linking specific quantified thresholds to management changes is still accumulating. Quantifying something precisely is not the same as knowing what to do with the number.

Regulatory status, indications, and labeling change over time. Confirm current status on the FDA's AI/ML-Enabled Medical Devices list and in the manufacturer's current instructions for use before relying on anything stated here.

← Back to FDA-Cleared AI Devices in Cardiology